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Seven hundred twenty-three isolates of Moraxella catarrhalis obtained from outpatients with a variety of
infections in 30 medical centers in the United States between 1 November 1994 and 30 April 1995 were
characterized in a central laboratory. The overall rate of b-lactamase production was 95.3%. When the
National Committee for Clinical Laboratory Standards MIC interpretive breakpoints for Haemophilus influ-
enzae were applied, percentages of strains found to be susceptible to selected oral antimicrobial agents were as
follows: azithromycin, clarithromycin, and erythromycin, 100%; tetracycline and chloramphenicol, 100%;
amoxicillin-clavulanate, 100%; cefixime, 99.3%; cefpodoxime, 99.0%; cefaclor, 99.4%; loracarbef, 99.0%; cefu-
roxime, 98.5%; cefprozil, 94.3%; and trimethoprim-sulfamethoxazole, 93.5%.
Moraxella catarrhalis is now recognized as a common cause
of a variety of localized, community-acquired infections, in
particular, acute otitis media, maxillary sinusitis, and acute
purulent exacerbation of chronic bronchitis (3, 7, 10). Most
clinical isolates of M. catarrhalis are found to produce one of
two b-lactamases, BRO-1 and BRO-2 (5, 8, 11, 12). Both of
these enzymes hydrolyze penicillin, ampicillin, and amoxicillin,
although to differing degrees (i.e., BRO-1 hydrolyzes them to
a greater extent than BRO-2) (5, 11). As a result, MICs of
penicillin, ampicillin, and amoxicillin are elevated for b-lacta-
mase-producing strains of M. catarrhalis, especially BRO-1 en-
zyme producers (1, 4, 6, 12). Whether production of either
enzyme is associated with clinical failures in patients treated
with these b-lactams has not been determined. Until such
information is available, however, prudence would dictate that
all infections caused by b-lactamase-producing M. catarrhalis,
irrespective of which enzyme is produced, be considered re-
fractile to management with penicillin, ampicillin, or amoxicil-
lin.
Two recent large multicenter surveillance studies in the
United States revealed overall rates of b-lactamase production
of 84.1% in 1987 and 1988 (6) and 92.0% in 1992 and 1993 (1).
Interestingly, there is some evidence that prior to 1976, in both
the United States and Europe, M. catarrhalis rarely if ever
produced b-lactamase (12).
Because the b-lactamases of M. catarrhalis are inhibited by
clavulanate, the combination drug amoxicillin-clavulanate has
been consistently active against this species (1, 4, 6). The same
is true of oral cephalosporins, excepting cephalexin and ce-
fadroxil (4). Erythromycin and tetracycline resistance has been
reported (2); however, the two most recent countrywide sur-
veillance studies in the United States during 1987 and 1993
failed to identify a single macrolide- or tetracycline-resistant
strain among a total of .1,000 isolates of M. catarrhalis. In
contrast, trimethoprim-sulfamethoxazole (TMP-SMX) resis-
tance is being reported with greater frequency (1).
The intent of the present study was to systematically deter-
mine the prevalence of antimicrobial resistance among current
isolates of M. catarrhalis in the United States. Between 1 No-
vember 1994 and 30 April 1995, a total of 723 different isolates
of this organism were prospectively collected from various
specimens from outpatients in 30 different U.S. medical cen-
ters. For further characterization, isolates were transported to
the University of Massachusetts Medical Center on rayon
swabs immersed in 12 ml of Amies semisolid transport medium
containing charcoal. Stock cultures were prepared with an ab-
sorbent-bead system (ProLab Diagnostics, Austin, Tex.), and
organisms were stored at 2708C until further use. All organ-
isms were subcultured twice on sheep blood agar plates prior
to further characterization. Isolates were confirmed as M. ca-
tarrhalis on the basis of Gram stain morphology and produc-
tion of oxidase and butyric acid esterase.
Susceptibility studies. MICs were determined by a broth
microdilution procedure (100-ml total volume per well; final
inoculum concentration, ca. 5 3 105 CFU/ml) in cation-adjust-
ed Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.),
with trays incubated at 358C in ambient air for 22 to 24 h prior
to determination of results. Sixteen antibiotics, obtained from
their respective manufacturers as laboratory-grade powders,
were each tested in 12 different concentrations in an attempt to
limit the number of off-scale results. The antimicrobial agents
were penicillin, ampicillin, amoxicillin, amoxicillin-clavulanate
(2:1), cefaclor, loracarbef, cefprozil, cefuroxime, cefixime, cef-
podoxime, erythromycin, azithromycin, clarithromycin, TMP-
SMX (1:19), chloramphenicol, and tetracycline. Staphylococcus
aureus ATCC 29213 and Escherichia coli ATCC 25922 were
used as controls. b-Lactamase production was assessed with all
isolates by the nitrocefin disk assay (Cefinase; Becton Dickin-
son Microbiology Systems, Cockeysville, Md.).
A total of 723 isolates of M. catarrhalis were characterized
(mean number contributed per medical center5 24.1; range5
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14 to 43). Males were the source of 57.2% of isolates. The
percentages of isolates obtained from patients in different age
groups were as follows: 0 to 5 years, 33.3%; 6 to 10 years, 4.8%;
11 to 20 years, 3.1%; 21 to 50 years, 18.2%; and .50 years,
40.6%. The percentages of isolates obtained from different
specimens were as follows: middle ear fluid, 4.5%; sinus aspi-
rates, 5.4%; conjunctival specimens, 7.4%; lower respiratory
tract, 80.3%; blood, 1.7%; and other, 0.8%.
Of the 723 isolates, 689 (95.3%) produced b-lactamase. MIC
results for 16 antimicrobial agents are listed in Table 1. MICs
of all 10 b-lactam antimicrobial agents examined in this study
were higher for b-lactamase-positive than b-lactamase-nega-
tive strains. Overall, ampicillin was equivalent to amoxicillin in
activity; both were more active than penicillin. The National
Committee for Clinical Laboratory Standards (NCCLS) cur-
rently does not provide MIC interpretive breakpoints for M.
catarrhalis (9). If current NCCLS MIC breakpoints for Hae-
mophilus influenzae (9) were applied, then 100% of the test
strains would have been categorized as susceptible to amoxi-
cillin-clavulanate.
As can be seen from the range of MICs listed in Table 1, not
all b-lactamase-positive strains would have been categorized as
ampicillin resistant according to the NCCLS Haemophilus
breakpoint of$4 mg/ml (9). Indeed, for 136 (19.7%) of the 689
b-lactamase-positive isolates, the MICs were #2 mg/ml. It is
likely that these strains produced the BRO-2 enzyme, which is
known to be associated with low penicillin and ampicillin MICs
due to small amounts of enzyme produced and low substrate
affinity (5, 11).
The activities of six oral cephalosporins were also examined
in this study. On the basis of current NCCLS Haemophilus
breakpoints (9), the percentages of strains determined to be
susceptible to the cephalosporins were 99.3% for cefixime,
99.0% for cefpodoxime, 99.4% for cefaclor, 99.0% for loracar-
bef, 98.5% for cefuroxime, and 94.3% for cefprozil. All non-
susceptible strains produced b-lactamase. With the exception
of the cefprozil MICs, the cephalosporin MICs obtained with
those strains categorized as not susceptible were only a single
doubling concentration higher than the susceptible MIC break-
points for the respective antimicrobial agents. In the case of
cefprozil, for 12 isolates (1.6% of the total) the MICs were$32
mg/ml, and these isolates would have been categorized as re-
sistant according to current NCCLS breakpoints for H. influ-
enzae (9).
Again on the basis of current Haemophilus breakpoints (9),
all isolates of M. catarrhalis were susceptible to the macrolides
examined in this study (erythromycin, azithromycin, and clar-
ithromycin). The same was true of chloramphenicol and tetra-
cycline. With TMP-SMX, the MICs for 6.5% of the isolates
were $1.0 mg/ml, and therefore, those isolates would have
been classified as intermediate (MICs 1 to 2 mg/ml; n 5 41) or
resistant (MICs, $4 mg/ml; n 5 6) according to the NCCLS
Haemophilus interpretive breakpoints (9).
It is apparent from the results of this study that today nearly
all clinical isolates ofM. catarrhalis produce b-lactamase and as
a result should probably be managed with agents other than
penicillin, ampicillin, or amoxicillin. Fortunately, this organism
remains uniformly susceptible to amoxicillin-clavulanate and
nearly uniformly susceptible to five oral cephalosporins, ce-
fixime, cefpodoxime, cefaclor, loracarbef, and cefuroxime.
Among these five agents, cefixime is clearly the most active.
Among non-b-lactam agents, three macrolides (azithromy-
cin, clarithromycin, and erythromycin), tetracycline, and chlor-
amphenicol were uniformly active; all strains were susceptible.
That was not true of TMP-SMX, to which only 93.5% of strains
were susceptible. Taken collectively, the results of this surveil-
lance study suggest that although rates of b-lactamase produc-
tion have increased slightly, M. catarrhalis has not changed
substantially in the context of antimicrobial resistance during
the period since the last large U. S. multicenter surveillance
study in 1992 and 1993 (3). A variety of oral antimicrobial
agents remain suitable for the management of outpatient M.
catarrhalis infections.
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TABLE 1. MICs of 16 antimicrobial agents obtained with 723 recent clinical isolates of M. catarrhalis
Antimicrobial agent
b-Lactamase-positive isolates (n 5 689) b-Lactamase-negative isolates (n 5 34)
MIC50a MIC90a MIC range MIC50 MIC90 MIC range
Penicillin 16 32 0.25–$32 0.03 0.03 #0.015–0.25
Ampicillin 4 16 0.06–.32 #0.015 0.03 #0.015–0.06
Amoxicillin 4 16 0.06–.32 #0.015 0.06 #0.015–0.12
Amoxicillin-clavulanate 0.25 0.5 #0.015–2 #0.015 0.06 #0.015–0.12
Cefaclor 1 2 0.03–16 0.5 0.5 0.12–0.5
Loracarbef 1 4 0.06–64 0.25 0.25 0.12–0.5
Cefprozil 4 8 0.06–64 1 1 0.25–1
Cefuroxime 2 4 0.06–32 0.5 0.5 0.12–1
Cefixime 0.25 0.5 #0.015–4 0.03 0.06 #0.015–0.25
Cefpodoxime 1 2 0.06–8 0.12 0.25 0.06–1
Erythromycin 0.25 0.25 0.06–1 0.12 0.25 0.06–0.25
Azithromycin 0.06 0.06 0.03–0.12 0.06 0.06 0.03–0.12
Clarithromycin 0.06 0.12 0.03–0.5 0.06 0.12 0.03–0.12
TMP-SMX 0.5 0.5 #0.06–8 0.25 0.5 #0.06–0.5
Chloramphenicol 0.5 1 0.25–2 0.5 1 0.5–1
Tetracycline 0.5 0.5 #0.06–1 0.5 0.5 #0.06–0.5
aMIC50 and MIC90, MICs at which 50 and 90% of isolates, respectively, are inhibited.
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